People · Operator
Named in public records as an officer, director or promoter · active 2010–2024 · Pharmaceuticals, Biotechnology, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Ardelyx, Inc. | — | Pharmaceuticals | Series D+ | $210.4M | $3.9B | 2016 |
| Sagimet Biosciences Inc. | — | Biotechnology | Series C | $166.6M | $2.4B | 2014 |
| Opus Genetics, Inc. | — | Biotechnology | Series B | $46.9M | $161.0M | 2024 |
| LoSo, Inc. | — | Other Technology | Pre-Seed | $100K | $4.2M | 2010 |
Richard Rodgers at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Richard Rodgers on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Mott | 2 | 9 |
| Gordon Ringold | 2 | 7 |
| Beth Seidenberg | 1 | 15 |
| Annalisa Jenkins | 1 | 8 |
| David Collier | 1 | 8 |
| Robert Garland | 1 | 7 |
| Cam Gallagher | 1 | 7 |
| Mina Sooch | 1 | 5 |
| Sean Ainsworth | 1 | 5 |
| Jeremy Caldwell | 1 | 4 |
| James Young | 1 | 4 |
| James Manuso | 1 | 4 |
| Peter G. Schultz | 1 | 3 |
| James S. Manuso | 1 | 3 |
| David Rosenbaum | 1 | 3 |
| John Curnutte | 1 | 2 |
| Rick Klausner | 1 | 2 |
| Jeff Jacobs | 1 | 2 |
| Richard J. Rodgers | 1 | 2 |
| Paul Korner | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.